Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $12.42, but opened at $12.03. Bicara Therapeutics shares last traded at $12.21, with a volume of 12,488 shares trading hands.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on BCAX shares. HC Wainwright raised their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, January 27th. Wedbush reaffirmed an "outperform" rating and set a $31.00 price objective on shares of Bicara Therapeutics in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $36.50.
Get Our Latest Report on BCAX
Bicara Therapeutics Stock Up 1.1 %
The company has a 50 day simple moving average of $12.98.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System purchased a new position in Bicara Therapeutics during the 4th quarter valued at about $25,000. Spire Wealth Management bought a new stake in Bicara Therapeutics during the fourth quarter valued at $31,000. BNP Paribas Financial Markets purchased a new position in Bicara Therapeutics during the fourth quarter worth about $32,000. Legal & General Group Plc bought a new position in Bicara Therapeutics in the 4th quarter worth about $33,000. Finally, Summit Investment Advisors Inc. purchased a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $35,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Further Reading
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
